Course Description
ADHD medication use among women of reproductive age has increased dramatically in recent years. Understanding both the risks of untreated symptoms and the risks of medications can inform treatment decisions that reduce risks. In this session, we’ll review gender influences on the presentation of ADHD, ADHD risks relevant to pregnancy, and a systematic approach to risk assessment. Through illustrative composite cases, we’ll compare risks of untreated symptoms to risks of medications for ADHD and some of its common comorbidities. We’ll discuss the role of nonpharmacologic interventions for ADHD. We’ll examine how risk/benefit analyses can change with the transition to motherhood, including considerations for women who are breastfeeding.
Learning Objectives
- Explain how to frame decisions about perinatal treatment of ADHD.
- List at least three risks of untreated ADHD that are relevant to pregnancy.
- Explain perinatal risks associated with commonly used ADHD medications.
- Describe how the risk/benefit analysis for use of ADHD medication can change postpartum.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Laura Miller, MD
Medical Director of Reproductive Mental Health, Office of Mental Health and Suicide Prevention
U.S. Department of Veterans Affairs
Chicago, IL
Laura J. Miller MD is the Medical Director of Reproductive Mental Health for the Veterans Health Administration. She is a Professor of Psychiatry at Loyola Stritch School of Medicine, and was previously Professor of Psychiatry at the University of Illinois at Chicago College of Medicine and Harvard Medical School. She graduated from Harvard Medical School and completed her psychiatry residency at the University of Chicago.
Dr. Miller has developed nationally award -winning women’s mental health services and educational programs, and has participated in numerous statewide and national women’s mental health policy initiatives. She has authored more than 80 articles and book chapters related to women’s mental health. She devotes her career to improving the mental health of women through clinical care, education and research.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Dates: 04/26/2022 - 04/26/2025
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-048-H04-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Program Committee
|
Elayne D. Ansara, PharmD, BCPP, BCPS Clinical Pharmacy Specialist Veteran Health Indiana Indianapolis, IN No Relevant Financial Relationships to Disclose |
 Jolene R. Bostwick, PharmD, BCPP, BCPSProgram Administrative Chair Assistant Dean for Co-Curriculum and Professional Development & Clinical Professor University of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
|
Bridget Bradley, PharmD, BCPP |
|
|
|
Chelsea N. Carr, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland School of Pharmacy Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Dana Chiulli, PharmD, BCPP Clinical Pharmacist - Mental Health VISN 06 Mental Health Clinical Resource Hub Savannah, GA No Relevant Financial Relationships to Disclose |
|
Jordan Cooler, PharmD, BCPP Clinical Assistant Professor University of South Carolina College of Pharmacy Columbia, SC No Relevant Financial Relationships to Disclose |
|
Bennett J. Doughty, PharmD, BCPP, BCPS |
|
Amber R. Douglass, PharmD, BCPS, BCPP Clinical Pharmacy Specialist - Mental Health VISN 1 Clinical Resource Hub - VA Connecticut Healthcare System West Haven, CT No Relevant Financial Relationships to Disclose |
Megan J. Ehret, PharmD, BCPP, MS |
|
Kristen N. Gardner, PharmD, BCPP |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Weitzman Institute Project ECHO Faculty |
|
Nicole Hahn, PharmD, BCACP Clinical Pharmacy Specialist - Neurology Kaiser Permanente Denver, CO No Relevant Financial Relationships to Disclose |
|
Kayla D. Johnson, PharmD, BCPP, BCPS Vanderbilt University Medical Center Thompsons Station, TN No Relevant Financial Relationships to Disclose |
|
Erin D. Knox, PharmD, BCPP Director of Experiential Education UCI School of Pharmacy & Pharmaceutical Sciences Irvine, CA Non-Financial Interests: Santa Ana Community College, Pharmacy Technology Program, Advisory Committee |
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP Dean and Professor University of Montana, Skaggs School of Pharmacy Missoula, MT External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Editorial Board member: Continuum: Lifelong Learning in Neuroilogy, consultant for Lexicomp as a clinical specialist in neurology and psychiatry |
|
Melissa Mitchell, PharmD, BCGP, BCPP, BCPS Senior Clinical Pharmacist RUHS MC Moreno Valley , CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Neurocrine Speakers Bureau - Ingrezza, Janssen Speakers Bureau - Spravato, Otsuka - PsychU.org Speaker |
|
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL No Relevant Financial Relationships to Disclose |
|
Lindsey Peters, PharmD, BCPS Associate Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Kristina Reinstatler, PharmD, BCPP, MBA Clinical Pharmacy Specialist UC Health University of Cincinnati Medical Center Cincinnati, OH Educational Grants, Research Grants or Contracts: HEALing Communities NIH grant- pharmacy lead Athens Cty, Ohio |
|
Michael D. Shuman, PharmD, BCPP Staff Pharmacist Central State Hospital Lousiville, KY No Relevant Financial Relationships to Disclose |
|
Taylor A. Thomas, PharmD, BCPP Clinical Pharmacy Specialist- Mental Health VA Northern Indiana Health Care System Fort Wayne, IN No Relevant Financial Relationships to Disclose |
|
Nina Vadiei, PharmD, BCPP Assistant Professor University of Arizona Colleges of Pharmacy and Medicine Tucson, AZ No Relevant Financial Relationships to Disclose |
Austin R. Campbell, PharmD, BCPPAll relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: bupropion, desipramine
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.